Linear estimates of rates of disease progression as predictors of survival in patients with ALS entering clinical trials

Journal of the Neurological Sciences

Volumn 160, Issue SUPPL. 1, 1998, Pages

  Armon, Carmel ^a   Moses, Dharmaseeli ^a  

^a LOMA LINDA UNIVERSITY   (United States)

Author keywords

Cox proportional hazards model; Forced vital capacity; Kaplan Meier method; Maximal voluntary isometric contraction; Survival

Indexed keywords

AMYOTROPHIC LATERAL SCLEROSIS; CONFERENCE PAPER; HUMAN; MUSCLE ISOMETRIC CONTRACTION; MUSCLE STRENGTH; PRIORITY JOURNAL; RISK ASSESSMENT; STATISTICAL ANALYSIS; VITAL CAPACITY;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; DISEASE PROGRESSION; FEMALE; FOOT; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 0031753445     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(98)00196-8     Document Type: Conference Paper

References (9)

1. Andres PL, Finison LJ, Conlon T, Thibodeau LM, Munsat TL. Use of composite scores (megascores) to measure deficit in amyotrophic lateral sclerosis. Neurology 1988;38:405-8.
2. Brooks BR, Sufit RL, DePaul R, Tan YD, Sanjak M, Robbins JA. Design of clinical therapeutic trials in amyotrophic lateral sclerosis. In: Rowland LP, editor. Advances in neurology, vol. 56. New York: Raven Press, 1991:521-46.
3. Munsat TL, Hollander D, Andres P, Finison L. Clinical trials in ALS: measurement and natural history. In: Rowland LP, editor. Advances in neurology, vol. 56. New York: Raven Press, 1991:515-9.
4. Smith RA, Melmed S, Sherman B, Frane J, Munsat TL, Festoff BW. Recombinant growth hormone treatment of amyotrophic lateral sclerosis. Muscle Nerve; June, 1993;16(6):624-33.
5. Armon C. Motor neuron disease. In: Gorelick PB, Alter M, editors. Handbook of neuroepidemiology. New York: Marcel Dekker, 1994:407-56.
6. Bryan WW, Barohn R, Murphy JR, Armon C, Miller RG, Goodpasture J, Parry GJ, Petajan J, Ross MA, Stromatt S. and the ALS/ SSNJV Study Group. Placebo versus natural history in an ALS clinical trial. Neurology 1995;45(Suppl 4):A280-1.
7. Miller RG, Petajan J, Bryan WW, Armon C, Barohn RJ, Goodpature JC, Hoagland RJ, Parry GJ, Ross MA, Stromatt S and the rhCNTF ALS Study Group. A placebo-controlled trial of recombinant human Ciliary Neurotrophic Factor (rhCNTF) in amyotrophic lateral sclerosis. Ann Neurol 1996;39:256-60.
8. Bradley WG, Fuller C and the BDNF Phase III Study Group. Phase III trial of recombinant methionyl human brain-derived neurotrophic factor. Neurology 1997;48:1728.
9. Strambler N, Charatan M, Cedarbaum JM and the ALS CNTF treatment study group. Prognostic indicators of survival in ALS. Neurology 1998;50(1):66-72.